Endochondral fracture healing with external fixation in the Sost knockout mouse results in earlier fibrocartilage callus removal and increased bone volume fraction and strength

Bone

Volumn 71, Issue , 2015, Pages 155-163

  Morse, A ^a,b   Yu, N Y C ^a,b,d   Peacock, L ^a   Mikulec, K ^a   Kramer, I ^c   Kneissel, M ^c   McDonald, M M ^a,e   Little, D G ^a,b  

^a CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c NOVARTIS PHARMA AG   (Switzerland)

^d UNIVERSITY OF NEW SOUTH WALES   (Australia)

^e GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

Bone; Endochondral; Fracture; Repair; Sclerostin; Sost

Indexed keywords

BUPRENORPHINE; SCLEROSTIN; GLYCOPROTEIN; SOST PROTEIN, MOUSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MASS; BONE STRENGTH; CALLUS; CONTROLLED STUDY; DISEASE COURSE; ENCHONDRAL OSSIFICATION; FEMALE; FIBROCARTILAGE; FRACTURE EXTERNAL FIXATION; FRACTURE HEALING; GENOTYPE; MOUSE; NONHUMAN; OSSIFICATION; POSTOPERATIVE PAIN; PROTEIN DEFICIENCY; PROTEIN EXPRESSION; SCLEROSTIN DEFICIENCY; TIBIA FRACTURE; ANIMAL; BIOMECHANICS; BONE DEVELOPMENT; C57BL MOUSE; DEFICIENCY; FRACTURE; FRACTURE FIXATION; IMMUNOHISTOCHEMISTRY; KNOCKOUT MOUSE; METABOLISM; MICRO-COMPUTED TOMOGRAPHY; ORGAN SIZE; PATHOLOGY; PATHOPHYSIOLOGY; RADIOGRAPHY; TIBIA;

ANIMALS; BIOMECHANICAL PHENOMENA; BONY CALLUS; FIBROCARTILAGE; FRACTURE FIXATION; FRACTURE HEALING; FRACTURES, CLOSED; GLYCOPROTEINS; IMMUNOHISTOCHEMISTRY; MICE, INBRED C57BL; MICE, KNOCKOUT; ORGAN SIZE; OSTEOGENESIS; TIBIA; TIBIAL FRACTURES; X-RAY MICROTOMOGRAPHY;

EID: 84909957930     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2014.10.018     Document Type: Article

References (40)

1. Semenov M., Tamai K., He X. SOST is a ligand for LRP5/LRP6 and a Wnt signaling inhibitor. J Biol Chem 2005, 280(29):26770-26775.
2. Poole K.E., van Bezooijen R.L., Loveridge N., Hamersma H., Papapoulos S.E., Lowik C.W., et al. Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation. FASEB J. Off. Publ. Fed. Am. Soc. Exp. Biol. 2005, 19(13):1842-1844.
3. van Bezooijen R.L., Bronckers A.L., Gortzak R.A., Hogendoorn P.C., van der Wee-Pals L., Balemans W., et al. Sclerostin in mineralized matrices and van Buchem disease. J Dent Res 2009, 88(6):569-574.
4. Jager A., Gotz W., Lossdorfer S., Rath-Deschner B. Localization of SOST/sclerostin in cementocytes in vivo and in mineralizing periodontal ligament cells in vitro. J Periodontal Res 2010, 45(2):246-254.
5. van Bezooijen R.L., Roelen B.A., Visser A., van der Wee-Pals L., de Wilt E., Karperien M., et al. Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist. J Exp Med 2004, 199(6):805-814.
6. van Bezooijen R.L., ten Dijke P., Papapoulos S.E., Lowik C.W. SOST/sclerostin, an osteocyte-derived negative regulator of bone formation. Cytokine Growth Factor Rev 2005, 16(3):319-327.
7. Glass D.A., Bialek P., Ahn J.D., Starbuck M., Patel M.S., Clevers H., et al. Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation. Dev Cell 2005, 8(5):751-764.
8. Spencer G.J., Utting J.C., Etheridge S.L., Arnett T.R., Genever P.G. Wnt signalling in osteoblasts regulates expression of the receptor activator of NFkappaB ligand and inhibits osteoclastogenesis in vitro. J Cell Sci 2006, 119(Pt 7):1283-1296.
9. Wijenayaka A.R., Kogawa M., Lim H.P., Bonewald L.F., Findlay D.M., Atkins G.J. Sclerostin stimulates osteocyte support of osteoclast activity by a RANKL-dependent pathway. PLoS One 2011, 6(10):e25900.
10. Kramer I., Halleux C., Keller H., Pegurri M., Gooi J.H., Weber P.B., et al. Osteocyte Wnt/beta-catenin signaling is required for normal bone homeostasis. Mol Cell Biol 2010, 30(12):3071-3085.
11. Staehling-Hampton K., Proll S., Paeper B.W., Zhao L., Charmley P., Brown A., et al. A 52-kb deletion in the SOST-MEOX1 intergenic region on 17q12-q21 is associated with van Buchem disease in the Dutch population. Am J Med Genet 2002, 110(2):144-152.
12. Balemans W., Ebeling M., Patel N., Van Hul E., Olson P., Dioszegi M., et al. Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). Hum Mol Genet 2001, 10(5):537-543.
13. Gardner J.C., van Bezooijen R.L., Mervis B., Hamdy N.A., Lowik C.W., Hamersma H., et al. Bone mineral density in sclerosteosis; affected individuals and gene carriers. J Clin Endocrinol Metab 2005, 90(12):6392-6395.
14. Loots G.G., Kneissel M., Keller H., Baptist M., Chang J., Collette N.M., et al. Genomic deletion of a long-range bone enhancer misregulates sclerostin in Van Buchem disease. Genome Res 2005, 15(7):928-935.
15. Kramer I., Kneissel M. The high bone mass phenotype of Sost deficient mice is characterized by progressive increase in bone thickness, mineralization and predicted cortical bone strength in a gene dosage unrelated manner. Bone 2008, 42(Suppl. 1(0)):S57.
16. Li X., Ominsky M.S., Niu Q.T., Sun N., Daugherty B., D'Agostin D., et al. Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength. J Bone Miner Res 2008, 23(6):860-869.
17. Li X., Warmington K.S., Niu Q.T., Asuncion F.J., Barrero M., Grisanti M., et al. Inhibition of sclerostin by monoclonal antibody increases bone formation, bone mass, and bone strength in aged male rats. J Bone Miner Res 2010, 25(12):2371-2380.
18. Li X., Ominsky M.S., Warmington K.S., Morony S., Gong J., Cao J., et al. Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis. J Bone Miner Res 2009, 24(4):578-588.
19. Li X., Warmington K.S., Niu Q.T., Asuncion F.J., Barrero M., Grisanti M., et al. Inhibition of sclerostin by monoclonal antibody increases bone formation, bone mass, and bone strength in aged male rats. J Bone Miner Res 2010, 25(12):2647-2656.
20. Ominsky M.S., Vlasseros F., Jolette J., Smith S.Y., Stouch B., Doellgast G., et al. Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strength. J Bone Miner Res 2010, 25(5):948-959.
21. Padhi D., Jang G., Stouch B., Fang L., Posvar E. Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. J Bone Miner Res 2011, 26(1):19-26.
22. McColm J., Hu L., Womack T., Tang C.C., Chiang A.Y. Single- and multiple-dose randomized studies of blosozumab, a monoclonal antibody against sclerostin, in healthy postmenopausal women. J Bone Miner Res 2014, 29(4):935-943.
23. McClung M.R., Grauer A., Boonen S., Bolognese M.A., Brown J.P., Diez-Perez A., et al. Romosozumab in postmenopausal women with low bone mineral density. N. Engl. J. Med 2014, 370(5):412-420.
24. Jawad M.U., Fritton K.E., Ma T., Ren P.G., Goodman S.B., Ke H.Z., et al. Effects of sclerostin antibody on healing of a non-critical size femoral bone defect. J Orthop Res 2013, 31(1):155-163.
25. McGee-Lawrence M.E., Ryan Z.C., Carpio L.R., Kakar S., Westendorf J.J., Kumar R. Sclerostin deficient mice rapidly heal bone defects by activating beta-catenin and increasing intramembranous ossification. Biochem Biophys Res Commun 2013, 441(4):886-890.
26. McDonald M.M., Morse A., Mikulec K., Peacock L., Yu N., Baldock P.A., et al. Inhibition of sclerostin by systemic treatment with sclerostin antibody enhances healing of proximal tibial defects in ovariectomized rats. J Orthop Res 2012, 30(10):1541-1548.
27. Agholme F., Li X., Isaksson H., Ke H.Z., Aspenberg P. Sclerostin antibody treatment enhances metaphyseal bone healing in rats. J Bone Miner Res 2010, 25(11):2412-2418.
28. Alaee F., Virk M.S., Tang H., Sugiyama O., Adams D.J., Stolina M., et al. Evaluation of the effects of systemic treatment with a sclerostin neutralizing antibody on bone repair in a rat femoral defect model. J Orthop Res 2014, 32(2):197-203.
29. Virk M.S., Alaee F., Tang H., Ominsky M.S., Ke H.Z., Lieberman J.R. Systemic administration of sclerostin antibody enhances bone repair in a critical-sized femoral defect in a rat model. J Bone Joint Surg Am 2013, 95(8):694-701.
30. Cui L., Cheng H., Song C., Li C., Simonet W.S., Ke H.Z., et al. Time-dependent effects of sclerostin antibody on a mouse fracture healing model. J Musculoskelet Neuronal Interact 2013, 13(2):178-184.
31. Ominsky M.S., Li C., Li X., Tan H.L., Lee E., Barrero M., et al. Inhibition of sclerostin by monoclonal antibody enhances bone healing and improves bone density and strength of nonfractured bones. J Bone Miner Res 2011, 26(5):1012-1021.
32. Li C., Ominsky M.S., Tan H.L., Barrero M., Niu Q.T., Asuncion F.J., et al. Increased callus mass and enhanced strength during fracture healing in mice lacking the sclerostin gene. Bone 2011, 49(6):1178-1185.
33. Schindeler A., McDonald M.M., Bokko P., Little D.G. Bone remodeling during fracture repair: the cellular picture. Semin Cell Dev Biol 2008, 19(5):459-466.
34. Le A.X., Miclau T., Hu D., Helms J.A. Molecular aspects of healing in stabilized and non-stabilized fractures. J Orthop Res 2001, 19(1):78-84.
35. Kramer I., Loots G.G., Studer A., Keller H., Kneissel M. Parathyroid hormone (PTH)-induced bone gain is blunted in SOST overexpressing and deficient mice. J Bone Miner Res 2010, 25(2):178-189.
36. Isefuku S., Joyner C.J., Simpson A.H. A murine model of distraction osteogenesis. Bone 2000, 27(5):661-665.
37. Robling A.G., Niziolek P.J., Baldridge L.A., Condon K.W., Allen M.R., Alam I., et al. Mechanical stimulation of bone in vivo reduces osteocyte expression of Sost/sclerostin. J Biol Chem 2008, 283(9):5866-5875.
38. Agholme F., Macias B., Hamang M., Lucchesi J., Adrian M.D., Kuhstoss S., et al. Efficacy of a sclerostin antibody compared to a low dose of PTH on metaphyseal bone healing. J Orthop Res 2014, 32(3):471-476.
39. Hill T.P., Spater D., Taketo M.M., Birchmeier W., Hartmann C. Canonical Wnt/beta-catenin signaling prevents osteoblasts from differentiating into chondrocytes. Dev Cell 2005, 8(5):727-738.
40. Tamamura Y., Otani T., Kanatani N., Koyama E., Kitagaki J., Komori T., et al. Developmental regulation of Wnt/beta-catenin signals is required for growth plate assembly, cartilage integrity, and endochondral ossification. J Biol Chem 2005, 280(19):19185-19195.